Sign Up to like & get
recommendations!
1
Published in 2023 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-23-306
Abstract: Background Recent studies have reported that the combination of immune checkpoint inhibitors (ICIs) and antiangiogenic agents could be a promising therapeutic strategy for advanced non-small cell lung cancer (NSCLC). However, both ICIs and antiangiogenic agents…
read more here.
Keywords:
immune checkpoint;
combination;
antiangiogenic agents;
icis antiangiogenic ... See more keywords